Measurable residual disease (MRD; previously termed minimal residual disease) is an
independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is …

Acute myeloid leukemia (AML) is the most common acute leukemia in adults, with an
incidence of over 20 000 cases per year in the United States alone. Large chromosomal …

Background Monitoring of measurable residual disease (MRD) in patients with advanced
myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) who achieve a …

Tumor tissue is composed of cancer cells and surrounding stromal cells with diverse
genetic/epigenetic backgrounds, a situation known as intra-tumoral heterogeneity. Cancer …

Purpose Patients with acute myeloid leukemia (AML) who are in morphologic complete
remission are typically considered separately from patients with active disease (ie,≥ 5 …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …

Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …

The past 40 years have witnessed major advances in defining the cytogenetic aberrations,
mutational landscape, epigenetic profiles, and expression changes underlying …

Minimal residual disease (MRD) before myeloablative hematopoietic cell transplantation
(HCT) is associated with adverse outcome in acute myeloid leukemia (AML) in first complete …

Purpose We investigated the effect on outcome of measurable or minimal residual disease
(MRD) status after each induction course to evaluate the extent of its predictive value for …